Celebrex patent loss to inflict EPS pain, but little more


A US district court reset Pfizer's Celebrex patent, allowing generics of the Cox-2 inhibitor to flow into the marketplace as early as May. The drugmaker thought it had an additional 15 months of patent-protected status based on a 2008 patent reissue.

Although the company pegged its 2014 outlook on 12 months of patented sales, the court's move does not put Pfizer completely off-balance: Pfizer had a March court date already set to discuss the patent, as indicated during its January earnings call.

Analyst reaction to Wednesday's court decision was relatively muted.

“Celebrex is a product that was going generic anyway and not a driver of growth,” Jami Rubin of Goldman Sachs noted in her March 12 analysis.

Bernstein analyst Tim Anderson wrote in his Thursday research note that a May generics rollout is not guaranteed, and that the news should do little to upset fans of a possible corporate breakup into three divisions, because Pfizer has emphasized that it would not contemplate a subdivision before 2017.

Should Pfizer lose its fight to reinstate the reissued patent, investors would likely feel an earnings-per-share impact, but the long-term corporate strategy is dependent upon more than one patent decision, even though it is a patented brand that brought in close to $3 billion in 2013 and experienced a 9% bounce compared to 2012.

“Short of splitting up, achieving any sort of meaningful revenue growth could be difficult unless the company were to do bigger M&A, which seems highly unlikely, or have terrific pipeline success,” Anderson wrote in his Thursday summary.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions